Renowned as one of the best hospitals in the US, with revenue of close to $12bn, non-profit organisation, The Mayo Clinic, has appointed Vice President and CEO of Mayo Clinic in Florida, Gianrico Farrugia, to succeed current leader Dr John Noseworthy upon his retirement at the end of the year.
The organisation has also recently completed a $3.76bn, eight-year philanthropic campaign, with total research and education funding surpassing $1bn in 2017. The organisation’s capital expenditures also reached $714mn, forming part of a multiyear plan to continue to invest in equipment, facilities and technology, including a new electronic health record and revenue cycle management system, network infrastructure and security upgrades.
Agreed by the Mayo Clinic Board of Trustees, Dr Noseworthy and Dr Farrugia will work closely together through this period of transition, as the clinic continues to provide exceptional care to over one million patients each year.
“We are deeply grateful for Dr Noseworthy’s outstanding patient-centered leadership and inspiration he provided over the past nine years,” says Samuel Di Piazza, chair, Mayo Clinic Board of Trustees.
“Mayo Clinic has had a tremendous track record under his leadership amidst unprecedented change in healthcare and is well-positioned for continued success as we make this transition.”
Dr Farrugia has been vice president, Mayo Clinic, and CEO of Mayo Clinic in Florida since January 2015, leading over 6,000 staff members. Since his appointment, Mayo Clinic’s Florida campus has established itself as the destination medical centre for the Southeast.
There have been significant investments in people, technology and expansion, including the opening of the new 190,000-square-foot Harry T. Mangurian Jr. Building for patients seeking cancer, neurology and neurosurgical care. In 2017, Mayo Clinic was named the best hospital in Florida in U.S. News & World Report’s Best Hospitals Honor Roll.
A native of Malta, Dr. Farrugia has spent 30 years as a Mayo physician, and is jointly appointed in the Division of Gastroenterology and Hepatology, Department of Internal Medicine, and the Department of Physiology and Biomedical Engineering.
“Dr Farrugia is a visionary and servant leader who brings with him a wealth of experience and knowledge ─ both as an innovator and an executive,” explained Dr Noseworthy. “In partnership with our staff across Mayo Clinic, and with a deep commitment to our values and mission, he will affirm Mayo Clinic’s position as the global health care leader for generations to come.”
With past experience as director of Mayo Clinic’s Center for Individualized Medicine, which is responsible for bringing genomics into routine clinical care, Dr Farrugia also was also the co-founder of the Center for Innovation at Mayo Clinic.
A member of the Mayo Clinic Board of Trustees and Mayo Clinic Board of Governors, Dr Farrugia is also a professor of medicine and physiology and a faculty member in biomedical engineering at Mayo Clinic Graduate School of Biomedical Sciences. Dr. Farrugia completed his undergraduate training at St. Aloysius College, Birkirkara, Malta, and earned his medical degree from the University of Malta Medical School.
He is the co-author of Think Big, Start Small, Move Fast: A Blueprint for Transformation From the Mayo Clinic Center for Innovation, a book highlighting the need for change in the delivery of health care. He has published more than 250 articles on genomics and the treatment of disorders of gastrointestinal motility.
“Dr. Farrugia brings an impressive depth of experience to this role,” noted Di Piazza. “A prolific investigator and inventor, and an accomplished executive, he has been at the leading edge of innovation across the breadth of Mayo’s clinical and research mission.”
“I am humbled and proud to follow and build upon this success with the best staff in the world,” commented Dr Farrugia. “While sea change continues to sweep through health care, I look forward to harnessing innovation, a hallmark of Mayo Clinic, to transform health care for the benefit of patients everywhere.”